checkpoint inhibitor

Difficult-to-treat bowel cancers respond in first study of new drug combination

Early results from a phase I trial in a small group of patients with advanced cancer using two drugs (nivolumab and pixatimod) that stimulate the immune system report that patients with bowel cancer may benefit from the combination.